TransCode Therapeutics Stock (NASDAQ: RNAZ) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 936.000 / 608.152K |
Day Range | - - - |
52 Wk Range | 0.421 - 356.000 |
Market Cap | $2.846M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 28 |
Short Interest | 0.69% |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of TransCode Therapeutics (NASDAQ: RNAZ) through any online brokerage.
Other companies in TransCode Therapeutics’s space includes: Dermata Therapeutics (NASDAQ:DRMA), Quoin Pharmaceuticals (NASDAQ:QNRX), Cyclacel Pharmaceuticals (NASDAQ:CYCC), Geovax Labs (NASDAQ:GOVX) and Finch Therapeutics Gr (NASDAQ:FNCH).
The latest price target for TransCode Therapeutics (NASDAQ: RNAZ) was reported by HC Wainwright & Co. on Tuesday, April 16, 2024. The analyst firm set a price target for 3.00 expecting RNAZ to rise to within 12 months (a possible 512.24% upside). 4 analyst firms have reported ratings in the last year.
The stock price for TransCode Therapeutics (NASDAQ: RNAZ) is $0.49 last updated Today at April 23, 2024 at 6:42 AM EDT.
There are no upcoming dividends for TransCode Therapeutics.
TransCode Therapeutics’s Q1 earnings are confirmed for Monday, May 13, 2024.
There is no upcoming split for TransCode Therapeutics.
TransCode Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.